DAFNA Capital Management’s Structure Therapeutics GPCR Stock Holding History

DAFNA Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5M	Hold	46,500	–	–	0.48%	42
2026 Q1	$2.24M	Buy	46,500 +9,500	+26%	+$650K	0.51%	42
2025 Q4	$2.57M	Sell	37,000 -22,000	-37%	-$898K	0.6%	40
2025 Q3	$1.65M	Hold	59,000	–	–	0.41%	51
2025 Q2	$1.22M	Hold	59,000	–	–	0.34%	53
2025 Q1	$1.02M	Buy	59,000 +23,500	+66%	+$576K	0.29%	56
2024 Q4	$963K	Buy	35,500 +1,500	+4%	+$53.2K	0.24%	58
2024 Q3	$1.49M	Buy	34,000 +29,000	+580%	+$1.12M	0.35%	54
2024 Q2	$196K	Buy	+5,000	New	+$205K	0.05%	80

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

DAFNA Capital Management's GPCR Position: Q2 2026 in Review

DAFNA Capital Management held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 46,500 shares worth $2.5M. The position accounts for 0.48% of the portfolio, ranked #42.

DAFNA Capital Management first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.57M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

DAFNA Capital Management held 46,500 shares of Structure Therapeutics worth $2.5M as of Q2 2026.
DAFNA Capital Management left its Structure Therapeutics share count unchanged in Q2 2026.
Structure Therapeutics made up 0.48% of DAFNA Capital Management's portfolio in Q2 2026, its #42 holding.
DAFNA Capital Management first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
DAFNA Capital Management's Structure Therapeutics position peaked at $2.57M in Q4 2025.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.